Mercer Global Advisors
INKT icon

Mercer Global Advisors’s MiNK Therapeutics INKT Stock Holding History

Mercer Global Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269 Buy
+23
New +$268 ﹤0.01% 5898

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $151M AUM

Mercer Global Advisors's INKT Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in MiNK Therapeutics (INKT) in Q2 2026: 23 shares worth $269. The stake represents ﹤0.01% of the portfolio and ranks #5898 among its holdings.

22 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Mercer Global Advisors held 23 shares of MiNK Therapeutics worth $269 as of Q2 2026.
  • MiNK Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • MiNK Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5898 holding.
  • 22 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.